Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients

• Status: Completed
• Trial end date: 2018-01-20
• Target enrollment: 0
• Participant gender: All

Summary

Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy obtaining sustained virologic response (SVR) in 77% of naïve patients with genotype 1-3 Studies rarely address the issues of improving host factors. The current study examines whether adding vitamin D with Peg/RBV, a potent immunomodulator, could improve viral response(SVR)compared to Peg/RBV.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hanyang University
• Collaborator: Roche Pharma AG

Criteria

Inclusion Criteria:

• Chronic genotype 1-3 HCV infection

• Treatment Naive

Exclusion Criteria:

• Child B and C

• HCC patients

• Pregnancy